Restoring blood flow may be best option to save your life and limb
Journal of the American Heart Association Report
- Amputation for severe blockages in the lower limbs has a lower survival rate than other treatment options that restore blood flow.
- Treatment options to restore blood flow to the lower limbs are less expensive than amputation.
Embargoed until 4 a.m. CT / 5 a.m. ET Wednesday, Aug. 15, 2018
DALLAS, Aug. 15, 2018 — Treatments that restore blood flow to the lower limbs of people with a serious circulation condition may be cheaper and associated with longer survival, than amputation according to new research in Journal of the American Heart Association, the Open Access Journal of the American Heart Association/American Stroke Association
The most severe form of peripheral artery disease, called critical limb ischemia, may result in ulcers on the leg, gangrene or the need for amputation.
“Many patients who are diagnosed with critical limb ischemia are told amputation is their only option,” said the study's lead author Jihad Mustapha, M.D., an interventional cardiologist and critical limb ischemia specialist at Advanced Cardiac & Vascular Amputation Prevention Centers in Grand Rapids, Michigan. “But amputation is associated with many poor outcomes, including shorter survival, depression and loss of independence.”
This is the first study to investigate long-term outcomes and costs associated with treating first major critical limb ischemia.
Researchers examined Medicare records of 72,199 patients diagnosed with primary critical limb ischemia from 2010 to 2015. Medicare is the primary payer for approximately 75 percent of critical limb ischemia-related hospitalizations and therefore represents the cross section of critical limb ischemia-related outcomes nationwide.
They estimated that 29 percent of patients diagnosed with critical limb ischemia either will die or have an amputation performed within the first year, and many will undergo several revascularization procedures during the median 3.5-year survival period of the study.
Over the four years of the study, researchers found:
- survival was 38 percent with endovascular revascularization (angioplasty with or without stenting);
- 40 percent with surgical revascularization (bypassing blocked vessels with vein grafts); and
- 23 percent among patients who underwent major amputation.
Annual healthcare costs during follow-up were $49,700 for endovascular revascularization, $49,200 for surgical revascularization, and $55,700 for amputation
“It's important that people know that amputation is not the only solution, so always get a second opinion,” Mustapha said.
In an accompanying editorial, Stephen Waldo, M.D., and Javier Valle, M.D., note: “these data demonstrate the significant clinical and financial burden that critical limb ischemia poses to our healthcare system. Considerable efforts are still needed to raise disease awareness and establish data that can guide further medical and procedural management given the critical importance of limb ischemia.”
Co-authors are Barry Katzen, M.D.; Richard Neville, M.D.; Robert Lookstein, M.D.; Thomas Zeller, M.D.; Larry Miller, Ph.D.; and Michael Jaff, D.O. Author disclosures are on the manuscript.
The Critical Limb Ischemia Society funded the study.
- Available multimedia is on the right column of the release link - https://newsroom.heart.org/news/restoring-blood-flow-may-be-best-option-to-save-your-life-and-limb?preview=337a7d8bde6e9b7b844ab6e682b449ce
- After Aug. 15, 2018, view the manuscript and editorial online.
- About Peripheral Artery Disease (PAD)
- Follow AHA/ASA news on Twitter @HeartNews
- For updates and new science from JAHA, follow @JAHA_AHA
Statements and conclusions of study authors published in American Heart Association scientific journals are solely those of the study authors and do not necessarily reflect the association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals. Foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and device corporations and health insurance providers are available at https://www.heart.org/en/about-us/aha-financial-information.
About the American Heart Association
The American Heart Association is devoted to saving people from heart disease and stroke – the two leading causes of death in the world. We team with millions of volunteers to fund innovative research, fight for stronger public health policies and provide lifesaving tools and information to prevent and treat these diseases. The Dallas-based association is the nation’s oldest and largest voluntary organization dedicated to fighting heart disease and stroke. To learn more or to get involved, call 1-800-AHA-USA1, visit heart.org or call any of our offices around the country. Follow us on Facebook and Twitter.
For Media Inquiries and AHA/ASA Spokesperson Perspective: 214-706-1173
Bridgette McNeill: 214-706-1135; firstname.lastname@example.org
For Public Inquiries: 1-800-AHA-USA1 (242-8721)